Unspecified time of fetal death, cause not specified ICD11 code: KD3B.Z
Mifepristone + misoprostol
Where permitted under national law and where culturally acceptable.
Oral > Solid: 200 mg + 200 µg ; 200 mg  + 200 µg  in co-package
EML status history
Adolescents and adults
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
The Committee recommended that the current listing of mifepristone + misoprostol on the core list of the EML be extended to include the new indication of medical management of intra-uterine fetal demise. The Committee noted evidence that the combination regimen was associated with higher rates of expulsion and shorter expulsion times than misoprostol alone. The Committee considered that adverse effects associated with use of the combination were generally mild, well-known and manageable. The Committee also noted that the medical management of intra-uterine fetal demise using this combination regimen has been included in WHO guidelines for medical management of abortion since 2018.